Skip to main content

A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)

Recruiting · Phase 1 · NCT06657768

Conditions: Alzheimer Disease, Healthy

At a glance

Research payments reported, 2025
$2.6M
U.S. investigators named
6
Sites paid
6
Planned or actual enrollment
128

About the trial

Sponsor
Eli Lilly and Company
Tested
LY4006895 (drug), Placebo (drug)
Dates
Started 2024-10-29; completion 2027-07
Results posted
Not yet

The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY4006895. Part A will administer a single-ascending dose in healthy participants or Part B will administer multiple-ascending doses in participants with early symptomatic Alzheimer's Disease (AD). Blood tests will be performed to check how much LY4006895 gets into the bloodstream and how long it takes the body to eliminate it. This is a 2-part study and will last approximately 29 weeks for Part A and 61 weeks for Part B, including a screening period for each part.

From ClinicalTrials.gov, last updated 2026-06-04. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Eli Lilly and Company reported $2.6M in research payments for this study in 2025 (8 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Collaborative Neuroscience Research LLC $1.8M
  • Trustees of Columbia Univ in The City of Ny $574,835
  • K2 Medical Research LLC $146,503
  • Duke University $52,836
  • Cenexel Iresearch LLC $35,000
  • Atlanta Center for Medical Research $5,216

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.